These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 25987463)

  • 1. Five biopsy specimens from the proximal part of the tumor reliably determine HER2 protein expression status in gastric cancer.
    Tominaga N; Gotoda T; Hara M; Hale MD; Tsuchiya T; Matsubayashi J; Kono S; Kusano C; Itoi T; Fujimoto K; Moriyasu F; Grabsch HI
    Gastric Cancer; 2016 Apr; 19(2):553-560. PubMed ID: 25987463
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ideal number of biopsy tumor fragments for predicting HER2 status in gastric carcinoma resection specimens.
    Ahn S; Ahn S; Van Vrancken M; Lee M; Ha SY; Lee H; Min BH; Lee JH; Kim JJ; Choi S; Jung SH; Choi MG; Lee JH; Sohn TS; Bae JM; Kim S; Kim KM
    Oncotarget; 2015 Nov; 6(35):38372-80. PubMed ID: 26460823
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor containing fragment number influences immunohistochemistry positive rate of HER2 in biopsy specimens of gastric cancer.
    Xu C; Liu Y; Ge X; Jiang D; Zhang Y; Ji Y; Hou J; Huang J; Su J; Zeng H; Qin J; Hou Y
    Diagn Pathol; 2017 May; 12(1):41. PubMed ID: 28549444
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of HER2 status between surgically resected specimens and matched biopsy specimens of gastric intestinal-type adenocarcinoma.
    Yoshida H; Yamamoto N; Taniguchi H; Oda I; Katai H; Kushima R; Tsuda H
    Virchows Arch; 2014 Aug; 465(2):145-54. PubMed ID: 24889042
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HER2 testing in paired biopsy and excision specimens of gastric cancer: the reliability of the scoring system and the clinicopathological factors relevant to discordance.
    Huang SC; Ng KF; Lee SE; Chen KH; Yeh TS; Chen TC
    Gastric Cancer; 2016 Jan; 19(1):176-82. PubMed ID: 25512144
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Matched biopsy and resection specimens of gastric and gastroesophageal adenocarcinoma show high concordance in HER2 status.
    Wang T; Hsieh ET; Henry P; Hanna W; Streutker CJ; Grin A
    Hum Pathol; 2014 May; 45(5):970-5. PubMed ID: 24656529
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Are biopsy specimens predictive of HER2 status in gastric cancer patients?
    Pirrelli M; Caruso ML; Di Maggio M; Armentano R; Valentini AM
    Dig Dis Sci; 2013 Feb; 58(2):397-404. PubMed ID: 22918687
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Usefulness and limitation of multiple endoscopic biopsy sampling for epidermal growth factor receptor and c-erbB-2 testing in patients with gastric adenocarcinoma.
    Kimura M; Tsuda H; Morita D; Shinto E; Tanimoto T; Ichikura T; Mochizuki H; Matsubara O
    Jpn J Clin Oncol; 2005 Jun; 35(6):324-31. PubMed ID: 15928192
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Extra-gain of HER2-positive cases through HER2 reassessment in primary and metastatic sites in advanced gastric cancer with initially HER2-negative primary tumours: Results of GASTric cancer HER2 reassessment study 1 (GASTHER1).
    Park SR; Park YS; Ryu MH; Ryoo BY; Woo CG; Jung HY; Lee JH; Lee GH; Kang YK
    Eur J Cancer; 2016 Jan; 53():42-50. PubMed ID: 26693898
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intratumoral and intertumoral heterogeneity of HER2 immunohistochemical expression in gastric cancer.
    Zhang H; Wang Y; Wang Y; Wu D; Lin E; Xia Q
    Pathol Res Pract; 2020 Nov; 216(11):153229. PubMed ID: 33010699
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Significant intratumoral heterogeneity of human epidermal growth factor receptor 2 status in gastric cancer: A comparative study of immunohistochemistry, FISH, and dual-color in situ hybridization.
    Kanayama K; Imai H; Yoneda M; Hirokawa YS; Shiraishi T
    Cancer Sci; 2016 Apr; 107(4):536-42. PubMed ID: 26752196
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HER2 Expression Status and Prognostic, Diagnostic, and Demographic Properties of Patients with Gastric Cancer: a Single Center Cohort Study from Iran.
    Feizy A; Karami A; Eghdamzamiri R; Moghimi M; Taheri H; Mousavinasab N
    Asian Pac J Cancer Prev; 2018 Jun; 19(6):1721-1725. PubMed ID: 29938472
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Does Specimen Type Have an Impact on HER2 Status in Endometrial Serous Carcinoma? Discordant HER2 Status of Paired Endometrial Biopsy and Hysterectomy Specimens in the Presence of Frequent Intratumoral Heterogeneity.
    Rottmann D; Assem H; Matsumoto N; Wong S; Hui P; Buza N
    Int J Gynecol Pathol; 2021 May; 40(3):263-271. PubMed ID: 32897955
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HER2 testing in advanced gastric and gastro-oesophageal cancer: analysis of an Australia-wide testing program.
    Kumarasinghe MP; Morey A; Bilous M; Farshid G; Francis G; Lampe G; McCue G; Von Neumann-Cosel V; Fox SB
    Pathology; 2017 Oct; 49(6):575-581. PubMed ID: 28823752
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immuno-Histochemical Assessment of HER2NEU Expression in Gastric Adenocarcinoma in North Karnataka, India.
    Nadaf AS; Rani H; Dinesh US
    Asian Pac J Cancer Prev; 2018 May; 19(5):1381-1385. PubMed ID: 29802704
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A large cohort of consecutive patients confirmed frequent HER2 positivity in gastric carcinomas with advanced stages.
    Cho J; Jeong J; Sung J; Sung CO; Kim KM; Park CK; Choi MG; Sohn TS; Bae JM; Kim S
    Ann Surg Oncol; 2013 Dec; 20 Suppl 3():S477-84. PubMed ID: 23274580
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Approaching heterogeneity of human epidermal growth factor receptor 2 in surgical specimens of gastric cancer.
    Asioli S; Maletta F; Verdun di Cantogno L; Satolli MA; Schena M; Pecchioni C; Botta C; Chiusa L; Molinaro L; Conti L; Viale G; Ingravallo G; Maiorano E; Sapino A
    Hum Pathol; 2012 Nov; 43(11):2070-9. PubMed ID: 22658277
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression and prognostic significance of human epidermal growth factor receptors 1, 2 and 3 in oesophageal and gastric adenocarcinomas preneoadjuvant and postneoadjuvant treatment.
    Hedner C; Borg D; Nodin B; Karnevi E; Jirström K; Eberhard J
    J Clin Pathol; 2018 May; 71(5):451-462. PubMed ID: 29138285
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of HER2 protein expression in gastric carcinomas: comparative analysis of 1,414 cases of whole-tissue sections and 595 cases of tissue microarrays.
    Kim KC; Koh YW; Chang HM; Kim TH; Yook JH; Kim BS; Jang SJ; Park YS
    Ann Surg Oncol; 2011 Oct; 18(10):2833-40. PubMed ID: 21468783
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical significance of intratumoral HER2 heterogeneity on trastuzumab efficacy using endoscopic biopsy specimens in patients with advanced HER2 positive gastric cancer.
    Yagi S; Wakatsuki T; Yamamoto N; Chin K; Takahari D; Ogura M; Ichimura T; Nakayama I; Osumi H; Shinozaki E; Suenaga M; Fujisaki J; Ishikawa Y; Yamaguchi K; Namikawa K; Horiuchi Y
    Gastric Cancer; 2019 May; 22(3):518-525. PubMed ID: 30328533
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.